Analystreport

Sutro Biopharma (NASDAQ:STRO) had its "buy" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.

Sutro Biopharma, Inc.  (STRO) 
Last sutro biopharma, inc. earnings: 11/8 07:00 am Check Earnings Report